Acciones Isodiol International Inc. Canadian Securities Exchange
Acciones
ISOL
CA46500L2003
Farmacéuticos
Ventas 2018 | 19,14 M 26,29 M 17,86 M | Ventas 2019 | 22,25 M 30,56 M 20,76 M | Capitalización | 49,96 M 68,62 M 46,62 M |
---|---|---|---|---|---|
Resultado Neto 2018 | -36 M -49,45 M -33,6 M | Resultado Neto 2019 | -126 M -173 M -118 M | VE / Ventas 2018 | 12,6 x |
Posición de caja neta 2018 | 15,55 M 21,36 M 14,51 M | Deuda neta 2019 | 5,22 M 7,17 M 4,87 M | VE / Ventas 2019 | 2,48 x |
P/E ratio 2018 |
-4,94
x | P/E ratio 2019 |
-0,37
x | Empleados | - |
Rendimiento 2018 * |
-
| Rendimiento 2019 |
-
| Flotante | 100 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 14/02/19 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Director/Board Member | - | 21/11/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+28,89 % | 5632,35 M | |
-32,73 % | 3567,46 M | |
-1,58 % | 3082,08 M | |
-24,27 % | 2649,45 M | |
-10,58 % | 2292,49 M | |
+49,91 % | 1990,14 M | |
+50,00 % | 1543,03 M | |
-11,78 % | 1447,19 M | |
+43,81 % | 1386,85 M |